HeartBeam, Inc. BEAT 深 滬
等待開盤 12-12 09:30:00 美东时间
2.12
+0.570
+36.77%
華盛通- 最 高2.8199
- 今 開1.45
- 成交量 1.60亿股
- 最 低 1.44
- 昨 收 1.55
- 總市值 7167.66万
- 52周最高 2.8199
- 市盈率 靜 --
- 換手率 472.24%
- 52周最低 0.54
- 委 比 -60.29%
- 總股本 3380.97万
- 歷史最高 71.96
- 量 比 2.89
- 振 幅 89.03%
- 歷史最低 0.54
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
今天 10:24
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
Why Is Micro Cap HeartBeam Stock Surging On Wednesday?
HeartBeam shares rise after FDA clears its 12-lead ECG software, boosting plans for a 2026 launch and expanded cardiac detection technology.
12-11 00:27
Why Is HeartBeam Stock (BEAT) Up Today?
HeartBeam stock gained alongside approval from the FDA for a heart monitoring d...
12-10 21:08
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
HC Wainwright & Co. Initiates Coverage On HeartBeam with Buy Rating, Announces Price Target of $2.5
HC Wainwright & Co. analyst Yi Chen initiates coverage on HeartBeam (NASDAQ:BEAT) with a Buy rating and announces Price Target of $2.5.
12-08 20:25
3 Penny Stocks to Watch Now, 12/2/25
Pasithea Therapeutics ($KTTA), Aditxt ($ADTX), and HeartBeam ($BEAT) are the 3&...
12-03 00:19
Heartbeam shares are trading higher after the company recently announced its regulatory strategy following the FDA's Not Substantially Equivalent decision on its 12-lead Electrocardiogram Synthesis Software.
Heartbeam shares are trading higher after the company recently announced its re...
11-29 00:23
Why Did Lazydays Holdings Stock Plunge 15% In After-Hours Trading?
Lazydays Holdings shares fell sharply in after-hours trading as the company completed $143.5 million in asset sales and prepares to delist from Nasdaq.
11-27 16:07
What's Behind HeartBeam's Over 40% After-Hours Surge?
HeartBeam shares jumped 40.75% in after-hours trading after the company outlined its regulatory strategy following the FDA's Not Substantially Equivalent decision.
11-27 14:37
